Going Underground
Largest study explores impact of dust on Tube staff
Researchers have carried out the largest study to date on the potential health impacts from
airborne dust on the London Underground.
Largest study explores impact of dust on Tube staff
Researchers have carried out the largest study to date on the potential health impacts from
airborne dust on the London Underground.
Most Powerful Scanner of its Kind Recognised at Royal Brompton
Celebration of the installation of the most powerful scanner of its kind in the centre of diagnostic expertise at Royal Brompton Hospital.
New heart treatment helps the body grow a replacement valve
Replacement heart valves that grow inside the body are a step closer to reality following studies led by researchers at Imperial.
Research shows how a tiny device in the ear canal can monitor heart health
A driving simulation study has shown we are one step closer to monitoring our heart health in real time via a tiny device worn in the ear.
An impactful year in 2023 for Imperial’s BHF Centre of Research Excellence
The BHF Centre of Research Excellence (CRE) looks back on a dynamic and successful 2023 as it approaches the final year of its award.
Professor Ken MacLeod leaving NHLI
Professor Ken MacLeod will be leaving the National Heart and Lung Institute at the end of 2023.
Heart stents may offer alternative to chest pain medication for angina patients
Some patients with chest pain from reduced blood flow to the heart may benefit from having a stent implanted, instead of chest pain medications.
AI stethoscope rolled out to 100 GP clinics to help diagnose heart failure
GP clinics in London and Wales will receive an AI-powered tool as part of a trial to help improve the diagnosis of a deadly heart condition.
How old is your heart? AI predicts “heart age” and pinpoints link to genes.
Scientists develop a new AI tool which calculates ‘Heart Age’ more accurately than ever and helps pinpoint genes for ageing.
Apollo Therapeutics raises $226.5m to develop medicines based on uni research
Company founded by the tech transfer offices of Imperial, Cambridge and UCL has raised major Series C funding to turn basic research into medicines.